It appears that this question requires some understanding of NF-κB signaling pathway. What is the take away from this mechanism? How would I have known that compound 2 itself will initiate the anti-apoptotic NF-kB signaling pathway when both comp 1&2 were administered simultaneously?
If there's a way to deduce it by figure analysis, could you please walk me through it? Thank you.
AAMC FL 4 CP 24
-
NS_Tutor_Mathias
- Posts: 616
- Joined: Sat Mar 30, 2019 8:39 pm
Re: AAMC FL 4 CP 24
No information from outside the passage is required here.
The answer key is simply stating that if both compounds are administered simultaneously, the NF-kB pathway won't be inhibited in every cell yet by the time camptothecin reaches them and starts acting. Thereby, the aptoposis-inhibiting NF-kB pathway (again: we know this from the passage) will activate and reduce the effectiveness of the drug.
At it's heart, this is a very simple question: You are told that Compound 1 sensitizes to Compound 2, and whether administering them simultaneously or 1 and then 2 makes more sense. You are given the data in figure 2 and the description of the pathway and of compound 1 as a sensitizing agent to base your answer on. The mechanical details don't even matter, although they are present within the passage.
The answer key is simply stating that if both compounds are administered simultaneously, the NF-kB pathway won't be inhibited in every cell yet by the time camptothecin reaches them and starts acting. Thereby, the aptoposis-inhibiting NF-kB pathway (again: we know this from the passage) will activate and reduce the effectiveness of the drug.
At it's heart, this is a very simple question: You are told that Compound 1 sensitizes to Compound 2, and whether administering them simultaneously or 1 and then 2 makes more sense. You are given the data in figure 2 and the description of the pathway and of compound 1 as a sensitizing agent to base your answer on. The mechanical details don't even matter, although they are present within the passage.